US Patent 11560381 Compounds and uses thereof

Is a

Patent

Patent attributes

Patent Applicant

Foghorn Therapeutics

Current Assignee

Foghorn Therapeutics

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

11560381

Date of Patent

January 24, 2023

Patent Application Number

17696656

Date Filed

March 16, 2022

Patent Citations

‌

US Patent 10905768 Heterocyclic degronimers for target protein degradation

‌

US Patent 10105420 Methods, compositions and screens for therapeutics for the treatment of synovial sarcoma

‌

US Patent 10646575 Heterocyclic degronimers for target protein degradation

‌

US Patent 10660968 Spirocyclic degronimers for target protein degradation

‌

US Patent 10849982 C3-carbon linked glutarimide degronimers for target protein degradation

‌

US Patent 11185592 Spirocyclic degronimers for target protein degradation

Patent Citations Received

‌

US Patent 11851445 Compounds and uses thereof

‌

US Patent 11691972 Compounds for targeted degradation of BRD9

‌

US Patent 11787800 BRD9 degraders and uses thereof

Patent Primary Examiner

CPC Code

The present invention relates to compositions and methods for the treatment of BAF-related disorders, such as cancers and viral infections.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

US Patent 11560381 Compounds and uses thereof

Contents

Patent attributes

Timeline

Further Resources

References

Find more entities like US Patent 11560381 Compounds and uses thereof